Dupont Capital Management Corp trimmed its stake in DexCom, Inc. (NASDAQ:DXCM) by 16.3% in the fourth quarter, Holdings Channel reports. The fund owned 7,250 shares of the medical device company’s stock after selling 1,412 shares during the quarter. Dupont Capital Management Corp’s holdings in DexCom were worth $416,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its holdings in shares of DexCom by 29.2% in the third quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock worth $431,510,000 after acquiring an additional 1,991,094 shares during the last quarter. Brown Advisory Inc. raised its holdings in shares of DexCom by 57.2% in the third quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock worth $203,798,000 after acquiring an additional 1,515,134 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of DexCom by 143.8% in the third quarter. JPMorgan Chase & Co. now owns 2,358,507 shares of the medical device company’s stock worth $107,170,000 after acquiring an additional 7,738,678 shares during the last quarter. State Street Corp raised its holdings in shares of DexCom by 2.5% in the second quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock worth $113,374,000 after acquiring an additional 37,581 shares during the last quarter. Finally, AXA increased its stake in DexCom by 10.5% in the third quarter. AXA now owns 1,318,931 shares of the medical device company’s stock valued at $64,529,000 after purchasing an additional 124,920 shares during the last quarter.
DXCM has been the subject of several analyst reports. TheStreet lowered DexCom from a “c-” rating to a “d+” rating in a research note on Wednesday, October 25th. BidaskClub upgraded DexCom from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 4th. Morgan Stanley dropped their target price on DexCom from $72.00 to $52.00 and set a “neutral” rating for the company in a research note on Friday, November 3rd. Northland Securities reiterated a “hold” rating and issued a $50.00 target price on shares of DexCom in a research note on Thursday, November 2nd. Finally, Zacks Investment Research lowered DexCom from a “hold” rating to a “sell” rating in a research note on Tuesday, October 24th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $68.50.
In other DexCom news, EVP Andrew K. Balo sold 6,490 shares of the company’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $60.00, for a total transaction of $389,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Barbara Kahn sold 3,000 shares of the company’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $54.58, for a total value of $163,740.00. Following the sale, the director now owns 4,353 shares of the company’s stock, valued at $237,586.74. The disclosure for this sale can be found here. Insiders have sold 48,140 shares of company stock valued at $2,743,281 over the last 90 days. 1.70% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: This report was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://sportsperspectives.com/2018/02/10/dupont-capital-management-corp-has-416000-stake-in-dexcom-inc-dxcm.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.